Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma—A Randomized, Placebo-Controlled Crossover Trial (MAPLE)

Yang, Freda; Busby, John; Heaney, Liam G.; Pavord, Ian; Brightling, Chris; Borg, Katie; McDowell, Jane P.; Diver, Sarah; Shrimanker, Rahul; Bradding, Peter; Shepherd, Malcolm; Chaudhuri, Rekha

doi:10.1016/j.jaip.2022.06.050

Cited by 8 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MAPLE trial was an exploratory, multi-centre, randomized, double-blind, placebo-controlled, crossover study of prednisolone in adults treated with mepolizumab at stable state. There was no significant clinical improvement with prednisolone 11 . In this manuscript, we report the planned transcriptomic and proteomic analysis of sputum, plasma, and nasal samples from the MAPLE trial, to test the hypothesis that prednisolone exerts additional anti-inflammatory effects to mepolizumab at stable state.…”

Section: Introductionmentioning

confidence: 84%

See 1 more Smart Citation

Anti-inflammatory effects of oral prednisolone at stable state in people treated with mepolizumab: a proteomic and bulk transcriptomics analysis

Howell,

Yang,

Brown

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Mepolizumab is an anti-interleukin-5 monoclonal antibody treatment for severe eosinophilic asthma (SEA) that reduces asthma exacerbations. Residual airway inflammation on mepolizumab may lead to persistent exacerbations. Oral corticosteroids have broad anti-inflammatory effects and remain the main treatment for these residual exacerbations. Our study aimed to explore the nature and corticosteroid-responsiveness of airway inflammation after mepolizumab treatment to find potentially treatable inflammatory mechanisms. The MAPLE trial was a multi-centre, randomized, double-blind, placebo-controlled, crossover study of 2 weeks of high-dose oral prednisolone treatment at stable state in patients treated with mepolizumab for SEA. We analysed sputum and plasma samples from the MAPLE trial using high-throughput Olink proteomics. We also analysed plasma microRNA, sputum proteins using ELISA, and nasal mucosal bulk RNA sequencing. In patients receiving mepolizumab, prednisolone significantly downregulated sputum proteins related to type-2 inflammation and chemotaxis including IL-4, IL-5, IL-13, CCL24, CCL26, EDN, CCL17, CCL22, OX40 receptor, FCER2, and the ST2 receptor. Prednisolone also downregulated cell adhesion molecules, prostaglandin synthases, mast cell tryptases, MMP1, MMP12, and neuroimmune mediators. Tissue repair and neutrophilic pathways were upregulated. Type-2 proteins were also downregulated in plasma, combined with IL-12, IFN-γ, and IP-10. IL-10 and amphiregulin were upregulated. In the nasal transcriptome, prednisolone suppressed genes involved in leucocyte chemotaxis, mast cell tryptase, 15-lipoxygenase and MMP12. By contrast, mepolizumab differentially regulated only Galectin-10 in plasma and no sputum proteins, and in nasal tissue affected genes related to cilia, keratinisation, extracellular matrix formation, and IL-4/13 signalling. At stable state, prednisolone has broad anti-inflammatory effects on top of mepolizumab.

show abstract

Section: Introductionmentioning

confidence: 84%

“…The MAPLE study population and design were described previously 11 . Briefly, participants were recruited before or after starting mepolizumab for usual clinical care.…”

Section: Methodsmentioning

confidence: 99%